1 |
LI H Q, ZHANG H, ZHANG H J, et al. Survival of gastric cancer in China from 2000 to 2022: a nationwide systematic review of hospital-based studies[J]. J Glob Health, 2022, 12: 11014.
|
2 |
SI L H, YANG Z C, DING L, et al. Regulatory effects of lncRNAs and miRNAs on the crosstalk between autophagy and EMT in cancer: a new era for cancer treatment[J]. J Cancer Res Clin Oncol, 2022, 148(3): 547-564.
|
3 |
龚 瑜, 杨其昌, 袁荣华, 等. 胃癌组织与血清miR-126的表达及临床意义[J]. 癌变·畸变·突变,2017, 29(4): 272-276, 283.
|
4 |
FENG R H, SAH B K, LI J F, et al. miR-126: an indicator of poor prognosis and recurrence in histologically lymph node-negative gastric cancer[J]. Cancer Biomark, 2018, 23(3): 437-445.
|
5 |
HAOYUAN M A, YANSHU L I. Structure, regulatory factors and cancer-related physiological effects of ADAM9[J]. Cell Adh Migr, 2020, 14(1): 165-181.
|
6 |
CHANDRASEKERA P, PERFETTO M, LU C Y, et al. Metalloprotease ADAM9 cleaves ephrin-B ligands and differentially regulates Wnt and mTOR signaling downstream of Akt kinase in colorectal cancer cells[J]. J Biol Chem, 2022, 298(8): 102225.
|
7 |
LIN Y S, HSIEH C Y, KUO T T, et al. Resveratrol-mediated ADAM9 degradation decreases cancer progression and provides synergistic effects in combination with chemotherapy[J]. Am J Cancer Res, 2020, 10(11): 3828-3837.
|
8 |
GAO H F, XU J J, QIAO F, et al. Depletion of hsa_circ_0000144 suppresses oxaliplatin resistance of gastric cancer cells by regulating miR-502-5p/ADAM9 axis[J]. Onco Targets Ther, 2021, 14: 2773-2787.
|
9 |
SOOFIYANI S R, HOSSEINI K, EBRAHIMI T,et al. Prognostic value and biological role of miR-126 in breast cancer[J]. Microrna, 2022, 11(2): 95-103.
|
10 |
YU J, FAN Q Q, LI L L. The MCM3AP-AS1/miR-126/VEGF axis regulates cancer cell invasion and migration in endometrioid carcinoma[J]. World J Surg Oncol, 2021, 19(1): 213.
|
11 |
YANG Q Y, YU Q, ZENG W Y, et al. Killing two birds with one stone: miR-126 involvement in both cancer and atherosclerosis[J]. Eur Rev Med Pharmacol Sci, 2022, 26(17): 6145-6168.
|
12 |
蒋莉萍, 赖铭裕, 蒋茂芹, 等. miR-126与靶基因GOLPH3在胃癌中的表达及其机制[J]. 实用医学杂志, 2020, 36(5): 623-627.
|
13 |
杜 昕, 曲 泽, 赵选忠, 等. miRNA-126和K-Ras及MMP-7在胃癌中的表达及其相关性分析[J]. 实用肿瘤学杂志, 2021, 35(1): 23-27.
|
14 |
魏海峰, 倪志强, 王起来, 等. 人胃癌组织中微小RNA-126和解整合素-金属蛋白酶9的表达及其与临床病理参数的相关性[J].中国医药, 2023, 18(11): 1678-1682.
|
15 |
HAOYUAN M A, YANSHU L I. Structure, regulatory factors and cancer-related physiological effects of ADAM9[J]. Cell Adh Migr, 2020, 14(1): 165-181.
|
16 |
MYGIND K J, SCHWARZ J, SAHGAL P, et al. Loss of ADAM9 expression impairs β1 integrin endocytosis, focal adhesion formation and cancer cell migration[J]. J Cell Sci, 2018, 131(1): jcs205393.
|
17 |
朱莉金, 罗 琰, 贾清玉, 等. ADAM9在实体肿瘤生物学中的相关研究进展[J]. 临床医学进展, 2020(10): 2270-2280.
|
18 |
ORIA V O, LOPATTA P, SCHMITZ T,et al. ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma[J].Mol Oncol,2019,13(2):456-479.
|
19 |
UENO M, SHIOMI T, MOCHIZUKI S, et al. ADAM9 is over-expressed in human ovarian clear cell carcinomas and suppresses cisplatin-induced cell death[J]. Cancer Sci, 2018, 109(2): 471-482.
|
20 |
ZHOU C C, LIU J B, LI Y,et al. microRNA-1274a,a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma[J].FEBS Lett,2011,585(12): 1828-1834.
|
21 |
OH S, PARK Y, LEE H J, et al. A disintegrin and metalloproteinase 9 (ADAM9) in advanced hepatocellular carcinoma and their role as a biomarker during hepatocellular carcinoma immunotherapy[J]. Cancers, 2020, 12(3): 745.
|
22 |
CHENG X S, SHEN T, LIU P, et al. miR-145-5p is a suppressor of colorectal cancer at early stage, while promotes colorectal cancer metastasis at late stage through regulating AKT signaling evoked EMT-mediated anoikis[J]. BMC Cancer, 2022, 22(1): 1151.
|
23 |
CHEN Y, FANG Y, LI L, et al. Exosomal miR-22-3p from mesenchymal stem cells inhibits the epithelial-mesenchymal transition (EMT) of melanoma cells by regulating LGALS1[J]. Front Biosci,2022,27(9): 275.
|
24 |
VAN KAMPEN J G M, VAN HOOIJ O, JANSEN C F,et al. miRNA-520f reverses epithelial-to-mesenchymal transition by targeting ADAM9 and TGFBR2[J]. Cancer Res, 2017, 77(8): 2008-2017.
|
25 |
DONG Y Y, WU Z F, HE M Y,et al.ADAM9 mediates the interleukin-6-induced Epithelial-Mesenchymal transition and metastasis through ROS production in hepatoma cells[J]. Cancer Lett, 2018, 421: 1-14.
|
26 |
LE T T, HSIEH C L, LIN I H, et al. The ADAM9/UBN2/AKR1C3 axis promotes resistance to androgen-deprivation in prostate cancer[J]. Am J Cancer Res, 2022, 12(1): 176-197.
|